Clinical trials
Terminated Primary Myelofibrosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
83 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 9 |
| 2007 | 6 |
| 2008 | 8 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 2 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 5 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 83 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Corporation | 8 |
| OHSU Knight Cancer Institute | 6 |
| City of Hope Medical Center | 4 |
| M.D. Anderson Cancer Center | 4 |
| Masonic Cancer Center, University of Minnesota | 4 |
| Mayo Clinic | 3 |
| University of Utah | 3 |
| Vanderbilt-Ingram Cancer Center | 3 |
| Astex Pharmaceuticals, Inc. | 2 |
| CTI BioPharma | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Primary Myelofibrosis | 83 |
| Myeloproliferative Disorders | 46 |
| Leukemia, Myeloid, Acute | 42 |
| Myelodysplastic Syndromes | 38 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 37 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 36 |
| Multiple Myeloma | 36 |
| Lymphoma, Non-Hodgkin | 31 |
| Lymphoma, Large B-Cell, Diffuse | 30 |
| Leukemia, Myelomonocytic, Chronic | 29 |
Trials
Showing 1 to 25 of 83. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.